Edgewise Reports Long-Term Becker Data, Preps Pivotal Readouts
Event summary
- Sevasemten shows sustained functional stabilization in Becker muscular dystrophy up to 3.5 years in MESA trial
- CIRRUS-HCM 12-week data for EDG-7500 in hypertrophic cardiomyopathy expected Q2 2026
- GRAND CANYON pivotal results for sevasemten in Becker anticipated Q4 2026
- Q1 2026 R&D expenses up 16% YoY to $42.7M, cash position at $499.6M
The big picture
Edgewise's long-term Becker data positions it as a potential first-mover in a rare disease space with no approved treatments. The company's dual focus on muscular dystrophy and cardiovascular indications aligns with growing investment in precision muscle therapeutics. With multiple readouts coming this year, Edgewise's execution will determine whether it can capitalize on this high-unmet-need market.
What we're watching
- Regulatory Pathway
- Whether GRAND CANYON results will support first marketing application for Becker muscular dystrophy in H1 2027
- Pipeline Progression
- The pace at which EDG-7500 advances to Phase 3 in hypertrophic cardiomyopathy following Q2 data
- Financial Runway
- How $499.6M cash position will support multiple near-term catalysts through 2026